Dasatinib (BMS-354825), a dual SRC/ABL tyrosine kinase inhibitor, inhibits tumor formation and prevents malignant ascites in a murine model of peritoneal carcinomatosis
Titel:
Dasatinib (BMS-354825), a dual SRC/ABL tyrosine kinase inhibitor, inhibits tumor formation and prevents malignant ascites in a murine model of peritoneal carcinomatosis
Auteur:
Lesslie, Donald Parikh, Nila Shah, Ami Summy, Justin Trevino, Jose Hong, David Donato, Nicholas Lee, Francis Gallick, Gary